Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Clinical course, predictors of development, and therapeutic response in multiple myeloma with central nervous system involvement

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYi LinMBMoritz BinderMGMorie A. Gertz

Discussion

Loading...

Member takes

Overview

Retrospective study reveals poor outcomes in CNS involvement of multiple myeloma, suggesting new treatment approaches are needed.

Key Points

  • Median overall survival for CNS involvement was 6 months, significantly worse than 15.6 months for extramedullary patients without CNS.
  • High-risk cytogenetics were prevalent in 73% of CNS-MM patients, indicating a need for monitoring and intervention.
  • Cerebrospinal fluid involvement was seen in 77% of CNS-MM patients, highlighting the aggressive nature of this disease.
  • Bispecific therapy resulted in a marked improvement in outcomes, contrasting with limited benefits from intrathecal therapy.

Cite This Study

Lin et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7d9https://doi.org/10.1182/blood-2025-2225
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement2026 · 1 citations
  2. 2Multiple myeloma with CNS involvement2025
  3. 3A Case Report Supporting the Use of Teclistamab in Multiple Myeloma With CNS Involvement2025 · 2 citations
  4. 4Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group2025
  5. 5Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition2025 · 2 citations